Research Analysts Offer Predictions for PAHC Q3 Earnings

Phibro Animal Health Co. (NASDAQ:PAHC) – Investment analysts at Zacks Research reduced their Q3 2025 earnings per share estimates for shares of Phibro Animal Health in a research note issued on Wednesday, November 20th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $0.35 for the quarter, down from their previous estimate of $0.37. The consensus estimate for Phibro Animal Health’s current full-year earnings is $1.61 per share. Zacks Research also issued estimates for Phibro Animal Health’s Q1 2026 earnings at $0.32 EPS, Q3 2026 earnings at $0.33 EPS and Q1 2027 earnings at $0.48 EPS.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings results on Wednesday, August 28th. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.07. The business had revenue of $273.16 million for the quarter, compared to analysts’ expectations of $262.44 million. Phibro Animal Health had a net margin of 1.67% and a return on equity of 21.59%.

Other research analysts have also issued research reports about the company. Barclays increased their target price on Phibro Animal Health from $13.00 to $20.00 and gave the stock an “underweight” rating in a research report on Tuesday, November 12th. Bank of America boosted their price objective on shares of Phibro Animal Health from $13.00 to $15.00 and gave the stock an “underperform” rating in a research note on Friday, August 30th. StockNews.com downgraded shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Finally, JPMorgan Chase & Co. began coverage on Phibro Animal Health in a research report on Tuesday, September 10th. They issued a “neutral” rating and a $22.00 price target on the stock. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, Phibro Animal Health has a consensus rating of “Hold” and an average target price of $16.50.

Phibro Animal Health Stock Performance

Shares of PAHC opened at $24.14 on Monday. The company has a 50-day simple moving average of $23.16 and a two-hundred day simple moving average of $20.03. The company has a debt-to-equity ratio of 1.81, a current ratio of 3.23 and a quick ratio of 1.69. The firm has a market capitalization of $977.67 million, a PE ratio of 55.21, a price-to-earnings-growth ratio of 0.61 and a beta of 0.51. Phibro Animal Health has a one year low of $9.49 and a one year high of $25.98.

Phibro Animal Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 18th. Shareholders of record on Wednesday, November 27th will be paid a dividend of $0.12 per share. The ex-dividend date is Wednesday, November 27th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.99%. Phibro Animal Health’s dividend payout ratio is currently 111.63%.

Insider Activity

In related news, Director E Thomas Corcoran acquired 5,000 shares of Phibro Animal Health stock in a transaction dated Wednesday, September 4th. The stock was purchased at an average cost of $20.02 per share, for a total transaction of $100,100.00. Following the purchase, the director now directly owns 25,000 shares of the company’s stock, valued at approximately $500,500. This trade represents a 25.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 50.07% of the company’s stock.

Institutional Trading of Phibro Animal Health

Several hedge funds have recently bought and sold shares of PAHC. CWM LLC lifted its position in shares of Phibro Animal Health by 89.8% during the 2nd quarter. CWM LLC now owns 2,188 shares of the company’s stock valued at $37,000 after buying an additional 1,035 shares in the last quarter. Quantbot Technologies LP purchased a new position in Phibro Animal Health during the third quarter valued at approximately $70,000. nVerses Capital LLC bought a new position in shares of Phibro Animal Health in the third quarter worth approximately $70,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Phibro Animal Health by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,912 shares of the company’s stock worth $88,000 after purchasing an additional 1,522 shares in the last quarter. Finally, Summit Securities Group LLC bought a new stake in shares of Phibro Animal Health during the 2nd quarter valued at $83,000. Institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.